文献速递特殊人群用药

妊娠期ETI母胎暴露的PBPK模型预测

Predicting Maternal and Fetal Exposures of Elexacaftor-Tezacaftor-Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models.
PubMed 文献 · Clin Pharmacol Ther · 2025-05-05

本研究用Simcyp妊娠PBPK模型预测依来曲福/替扎卡福/依伐卡福(ETI)在妊娠期的母体与胎儿暴露,并评估维持治疗浓度所需剂量。模型预测与观察数据吻合,至孕40周AUC降至基线32.4-37.5%,但母胎 trough 第5百分位仍高于疗效阈值,提示可维持标准剂量并加强监测。

要点

  • 孕40周ETI的AUC降至基线32.4-37.5%,但母胎 trough 第5百分位仍高于疗效阈值
  • 模型预测的母体血浆、脐带血和婴儿血浆浓度多落在预测5-95百分位内
  • 可维持妊娠期标准剂量,但需仔细监测,并待MAYFLOWERS等临床试验确认

核心结论

  • 妊娠期维持ETI标准剂量似乎是合理的,但需结合仔细监测,并需临床试验进一步确认疗效与安全性。

研究设计与样本

  • 研究采用Simcyp Simulator中的妊娠生理药代动力学(PBPK)模型,预测ETI的母体与胎儿-胎盘暴露。
  • 胎盘动力学用根据化合物理化性质确定的渗透性参数进行参数化。

主要发现

  • 模型预测与观察数据吻合,观察到的ETI母体血浆浓度、脐带浓度和婴儿血浆浓度大多落在预测的第5至95百分位范围内。
  • 至孕40周的稳态模拟预测ETI浓度持续下降,AUC降至基线水平的32.4-37.5%。
  • 母体和胎儿中ETI谷浓度的第5百分位始终高于疗效阈值。

临床怎么用

  • 妊娠期可考虑维持ETI标准给药方案,并辅以仔细监测。

局限性

  • 结论基于PBPK模型预测,尚需如MAYFLOWERS等临床试验进一步确认ETI在该人群中的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with increased fertility in women with cystic fibrosis (CF) and is increasingly used during pregnancy to support both maternal and fetal health. However, little is known about the pharmacokinetics (PK) of ETI during pregnancy, which is crucial for optimizing its efficacy and safety. This study aimed to predict the PK of ETI during pregnancy and to determine the maternal dose required to achieve therapeutic concentrations in both the maternal and fetus. The pregnancy physiological-based pharmacokinetic (PBPK) model within the Simcyp Simulator was used to predict the maternal and feto-placental exposure of ETI. Placental kinetics were parameterized using permeability parameters determined from the physicochemical properties of these compounds. The model closely predicted the observed data, with the observed ETI maternal plasma concentrations, cord concentrations, and infant plasma concentrations mostly falling within the range of predicted 5th to 95th percentiles. Steady-state simulations up to gestational week 40 predicted a continuous decline in ETI concentrations, with the AUC declining to 32.4-37.5% of baseline levels by week 40. However, the 5th percentile of trough concentrations for ETI consistently remained above the efficacy thresholds, both in mother and fetus. Therefore, it appears reasonable to maintain standard dosing regimen during pregnancy, complemented by careful monitoring. A clinical trial, such as the ongoing Maternal and Fetal Outcomes in the Era of Modulators (MAYFLOWERS) study, is required to further confirm the efficacy and safety of ETI in this population.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hong E, Hebert MF, Fay E, et al. Predicting Maternal and Fetal Exposures of Elexacaftor-Tezacaftor-Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models. Clin Pharmacol Ther. 2025. PMID: 40323155. doi:10.1002/cpt.3705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。